BACKGROUND: This study estimated the healthcare resource utilisation and costs of chronic obstructive pulmonary disease (COPD) patients, staged by severity, in the Italian pneumology departments (PDs). METHODS: The project was a multi-centre observational study conducted in 11 Italian PDs throughout the country. A total of 268 patients were recruited and followed prospectively for 1 year. For the purpose of analysis, patients were divided into four groups according to the severity at onset: mild COPD (stage I)-postbronchodilator FEV1/FVC <70% and FEV1 >or=80% of predicted; moderate COPD (stage II)-postbronchodilator FEV1/FVC <70% and 50% <or=FEV1< 80% of predicted; severe COPD (stage III)-postbronchodilator FEV1/FVC <70% and 30% <or=FEV1 <50% of predicted; very severe COPD (stage IV)-postbronchodilator FEV1/FVC <70% and FEV1 <30% of predicted, or clinical signs of either respiratory or cardiac failure. RESULTS: Subgroups differed significantly in the main demographic and clinical variables. Broadly, higher severity was associated with older age, longer disease duration, and more frequent exacerbations. Patients with severe COPD used more resources for almost all services than those with mild and moderate forms. The annual average cost per patient was 3040.2 euros (1046.7 euros for mild, 2319.0 euros for moderate, 3572.1 euros for severe and 5033.3 euros for very severe forms). CONCLUSIONS: This study offers some information on the healthcare costs of COPD induced by PDs in Italy, potentially useful for decision-making in the health care services. Resources and costs rose significantly with disease severity.
BACKGROUND: This study estimated the healthcare resource utilisation and costs of chronic obstructive pulmonary disease (COPD) patients, staged by severity, in the Italian pneumology departments (PDs). METHODS: The project was a multi-centre observational study conducted in 11 Italian PDs throughout the country. A total of 268 patients were recruited and followed prospectively for 1 year. For the purpose of analysis, patients were divided into four groups according to the severity at onset: mild COPD (stage I)-postbronchodilator FEV1/FVC <70% and FEV1 >or=80% of predicted; moderate COPD (stage II)-postbronchodilator FEV1/FVC <70% and 50% <or=FEV1< 80% of predicted; severe COPD (stage III)-postbronchodilator FEV1/FVC <70% and 30% <or=FEV1 <50% of predicted; very severe COPD (stage IV)-postbronchodilator FEV1/FVC <70% and FEV1 <30% of predicted, or clinical signs of either respiratory or cardiac failure. RESULTS: Subgroups differed significantly in the main demographic and clinical variables. Broadly, higher severity was associated with older age, longer disease duration, and more frequent exacerbations. Patients with severe COPD used more resources for almost all services than those with mild and moderate forms. The annual average cost per patient was 3040.2 euros (1046.7 euros for mild, 2319.0 euros for moderate, 3572.1 euros for severe and 5033.3 euros for very severe forms). CONCLUSIONS: This study offers some information on the healthcare costs of COPD induced by PDs in Italy, potentially useful for decision-making in the health care services. Resources and costs rose significantly with disease severity.
Authors: Tina Riegels-Jakobsen; Malene Skouboe; Jens Dollerup; Christian Buus Andersen; Louise Barkan Staal; Rolf B H Jakobsen; Peter Bo Poulsen Journal: Int J Chron Obstruct Pulmon Dis Date: 2012-02-01
Authors: Carl Selya-Hammer; Nuria Gonzalez-Rojas Guix; Michael Baldwin; Andrew Ternouth; Marc Miravitlles; Maureen Rutten-van Mölken; Lucas M A Goosens; Nasuh Buyukkaramikli; Valentina Acciai Journal: Ther Adv Respir Dis Date: 2016-07-12 Impact factor: 4.031